Home > Insider Trading > Filing (0000899243-17-024684)

Filing Details

Accession Number:: 0000899243-17-024684
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-10-25 16:05:32
Reporting Period:: 2017-10-23

Accepted Time:: 2017-10-25 16:05:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1389147	George Stephen Dilly	Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane CA 94005-1884	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	75,468	$33.23	339,840	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	17,472	$34.15	322,368	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	6,960	$35.39	315,408	No	4	S	Direct
Common Stock, $0.0001 Par Value	Disposition	2017-10-23	100	$36.55	315,308	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	41,075	Indirect	By Child's Trust 1
Common Stock, $0.0001 Par Value	20,656	Indirect	By Family Trust
Common Stock, $0.0001 Par Value	41,075	Indirect	By Child's Trust 2
Common Stock, $0.0001 Par Value	14,447	Indirect	By GRAT 2
Common Stock, $0.0001 Par Value	14,447	Indirect	By Wife's GRAT 2

Footnotes

This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
The transaction was executed in multiple trades in prices ranging from $32.79 to $33.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
A portion of these shares is subject to a right of repurchase held by the Issuer.
The transaction was executed in multiple trades in prices ranging from $33.79 to $34.77, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $34.79 to $35.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
These shares are held by the Frederick S W Dilly Trust. Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.
These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Dilly Family Trust dated October 9, 2002 (the "Family Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Family Trust.
These shares are held by the Harriet F.L. Dilly Trust. Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.
These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust.
These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust.